1 March 1995 Meta-tetrahydroxyphenylchlorin (mTHPC) mediated photodynamic therapy: experience and thoughts after 17 treatments
Author Affiliations +
Proceedings Volume 2371, 5th International Photodynamic Association Biennial Meeting; (1995) https://doi.org/10.1117/12.203353
Event: Fifth International Photodynamic Association Biennial Meeting, 1994, Amelia Island, FL, United States
Abstract
Over the past 14 months we have treated a wide variety of head and neck cancer patients with mTHPC mediated photodynamic therapy. This drug is a very powerful second generation photosensitizer with significant advantages over earlier drugs. Patients treated range from palliative to primary (curative) to adjunctive (intraoperative) cases. Following promising results we are now setting up a multicenter European study to treat early head and neck cancer with this drug/light combination, along with other collaborative studies to look further at the role of adjunctive PDT.
© (1995) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Mike G. Dilkes, Mike G. Dilkes, Martin L. DeJode, Martin L. DeJode, } "Meta-tetrahydroxyphenylchlorin (mTHPC) mediated photodynamic therapy: experience and thoughts after 17 treatments", Proc. SPIE 2371, 5th International Photodynamic Association Biennial Meeting, (1 March 1995); doi: 10.1117/12.203353; https://doi.org/10.1117/12.203353
PROCEEDINGS
6 PAGES


SHARE
Back to Top